In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Prenatal screening describes tests that detect potential problems that affect the viability and development of the fetus using both less invasive and more invasive sampling techniques. GlobalData uses proprietary data and analytics to provide a comprehensive report on the prenatal screening devices market, including market shares of different players within Australia. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the prenatal screening market in Australia was Illumina followed by F. Hoffmann-La Roche, Ortho Clinical Diagnostics, Danaher, BGI Genomics, Thermo Fisher Scientific, PerkinElmer, Eurofins Scientific, Siemens and Abbott Laboratories.
This market includes the sub-segments Free Beta Human Chorionic Gonadotropin (hCG) Tests, Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests, Alpha-Fetoprotein (AFP) Tests, and Inhibin A Tests.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the prenatal screening devices market within Australia was expected to be over $10m in 2022.
For the latest complete market share analysis of prenatal screening device market in Australia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
